



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 6 Feb 2023 (#06)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Important Notices

NOT-HD-23-004 Notice of Clarification for the Research Scope in **RFA-HD-24-002** "Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)". The purpose of this Notice is to alert potential applicants of a clarification in the Research Scope section to ensure the criteria match the intention of the Branch and align with the current Branch Research Priorities.

Notices of Special Interest (NOSI)

NOT-HL-23-066 Notice of Special Interest (NOSI): **Development of Functional Assay Sites to Evaluate Candidate - Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01)**. Large-scale, high-throughput sequencing studies, such as the NHLBI [Trans-Omics for Precision Medicine](#) (TOPMed) program and the NHGRI Genome Sequencing Program, have identified hundreds of millions of genetic variants potentially associated with numerous heart, lung, blood and sleep (HLBS) clinical phenotypes. The challenge now is to distinguish which are pathogenic and clinically significant, and at a level of scale capable of generating a knowledge base of annotated variants with sufficient breadth and depth to inform clinical care.

Biological functional assays are one approach to validating candidate disease variants. However, these assays are highly specific for the physiology of the target disease, require specialized expertise, and may be difficult or expensive to replicate in multiple research labs. Therefore, in order to accelerate development of assays to validate candidate variants, the NHLBI is seeking research applications from academic and small business entities proposing to design and conduct biological functional assays. Broad systems-level approaches are encouraged over single-gene or single-gene variant assessments.

The NHLBI is issuing this Notice of Special Interest (NOSI) to highlight interest in receiving grant applications focused on HLBS disorders in the following area(s):

- Development and/or application of moderate- or high-throughput functional assays to provide biological validation of candidate human variants associated with HLBS disorders
- Defining causal relationships between genotypes and phenotypes
- Development and validation of functionally informed risk predictions

This notice applies to due dates on or after April 5, 2023, and subsequent receipt dates through September 7, 2026.

NOT-NS-23-042 Administrative Supplements: Harmonization and Joint Analysis of Human Brain Single-Cell Datasets.

The [NIH Blueprint for Neuroscience Research](#) (BP) is soliciting Administrative Supplement applications that support the joint analysis of existing disease-focused and Brain Research Through Advancing Neurotechnologies (BRAIN) Initiative-generated “control” datasets of single-cell/nucleus data from human brain. Projects that are currently funded to analyze single-cell/nucleus datasets from human pre- or post-mortem brain tissue are eligible to apply. Projects that do not have an active analysis component are not eligible. This supplement program strongly encourages direct collaborations between investigators funded by the BRAIN Initiative and investigators funded by participating NIH BP Institutes or Centers. Supplemental funding will not support data generation, analysis of non-human data, analysis of non-brain tissues, or the generation of harmonized datasets that lack a clearly described plan for timely deposition (12 months from start date) for broad sharing. Application Due Date: May 1, 2023, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcements (FOA)

1. Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-24-018](#)

Type: R21/R33

Application Due Date: **September 22, 2023.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications proposing to establish new, or significantly expand existing, interdisciplinary collaborations involving both experimental and computational researchers to simultaneously address a targeted research question in brain aging and Alzheimer's disease (AD), including AD-related dementias (ADRD). This FOA utilizes the R21/R33 Phased Innovation Award activity code. The R21 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities. The aim of this initiative is for investigators to develop a sustainable, interdisciplinary collaboration across experimental and computational laboratories to support projects that address key research questions in brain aging and AD/ADRD.

Budget: NIA intends to commit \$2,000,000 in FY 2024 to fund 8 to 10 awards. For the R21 phase, the combined budget for direct costs for a two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. For the R33 phase, application budgets must remain under \$500,000 in annual direct costs. The duration of the entire R21/R33 award may not exceed 5 years. The R21 phase may not exceed 2 years of support. The R33 phase may not exceed 3 years of support.

Research Development and Support Division (RDSD) &
Grants Management Office (GMO)
Faculty of Medicine and Health Sciences
Kth Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105